Levin Capital Strategies’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.09M Buy
6,291
+138
+2% +$74.9K 0.23% 87
2025
Q4
$3.57M Hold
6,153
0.31% 61
2025
Q3
$2.98M Sell
6,153
-34
-0.5% -$15.8K 0.27% 62
2025
Q2
$2.51M Hold
6,187
0.24% 66
2025
Q1
$3.08M Hold
6,187
0.33% 62
2024
Q4
$3.22M Sell
6,187
-18
-0.3% -$9.9K 0.3% 61
2024
Q3
$3.84M Sell
6,205
-27
-0.4% -$16K 0.37% 55
2024
Q2
$3.45M Sell
6,232
-41
-0.7% -$23.5K 0.36% 54
2024
Q1
$3.65M Sell
6,273
-220
-3% -$123K 0.36% 55
2023
Q4
$3.45M Hold
6,493
0.37% 52
2023
Q3
$3.29M Sell
6,493
-420
-6% -$224K 0.39% 50
2023
Q2
$3.61M Sell
6,913
-116
-2% -$62.6K 0.41% 49
2023
Q1
$4.05M Sell
7,029
-130
-2% -$73.3K 0.5% 45
2022
Q4
$3.94M Sell
7,159
-23
-0.3% -$12.2K 0.53% 45
2022
Q3
$3.64M Buy
7,182
+292
+4% +$163K 0.49% 46
2022
Q2
$3.74M Sell
6,890
-6,412
-48% -$3.53M 0.44% 52
2022
Q1
$7.86M Sell
13,302
-3,193
-19% -$1.83M 0.76% 42
2021
Q4
$11M Sell
16,495
-320
-2% -$200K 1.03% 33
2021
Q3
$9.61M Sell
16,815
-244
-1% -$134K 0.96% 34
2021
Q2
$8.61M Sell
17,059
-2,711
-14% -$1.28M 0.88% 34
2021
Q1
$9.02M Sell
19,770
-5,733
-22% -$2.74M 0.96% 27
2020
Q4
$11.9M Sell
25,503
-1,088
-4% -$510K 1.33% 24
2020
Q3
$11.7M Sell
26,591
-134
-0.5% -$55.4K 1.54% 23
2020
Q2
$9.68M Sell
26,725
-13,595
-34% -$4.56M 1.33% 26
2020
Q1
$11.4M Sell
40,320
-1,630
-4% -$514K 1.85% 18
2019
Q4
$13.6M Sell
41,950
-206
-0.5% -$62.5K 1.36% 27
2019
Q3
$12.3M Sell
42,156
-4,336
-9% -$1.24M 1.36% 26
2019
Q2
$13.7M Sell
46,492
-125
-0.3% -$34.4K 1.35% 27
2019
Q1
$12.8M Sell
46,617
-1,571
-3% -$391K 1.43% 24
2018
Q4
$10.8M Sell
48,188
-1,228
-2% -$288K 0.24% 58
2018
Q3
$12.1M Sell
49,416
-230
-0.5% -$52.9K 0.21% 57
2018
Q2
$10.3M Sell
49,646
-2,225
-4% -$472K 0.18% 61
2018
Q1
$10.7M Sell
51,871
-5,260
-9% -$1.1M 0.19% 59
2017
Q4
$10.8M Sell
57,131
-1,685
-3% -$323K 0.18% 60
2017
Q3
$11.1M Sell
58,816
-2,977
-5% -$539K 0.19% 64
2017
Q2
$10.8M Sell
61,793
-680
-1% -$114K 0.19% 64
2017
Q1
$9.6M Sell
62,473
-669,521
-91% -$102M 0.17% 65
2016
Q4
$103M Buy
731,994
+670,206
+1,085% +$98.8M 1.77% 20
2016
Q3
$9.83K Sell
61,788
-1,436
-2% -$221K 0.14% 81
2016
Q2
$9.34M Sell
63,224
-2,770
-4% -$409K 0.17% 78
2016
Q1
$9.34M Sell
65,994
-2,955
-4% -$396K 0.17% 80
2015
Q4
$9.78M Sell
68,949
-390
-0.6% -$52K 0.17% 84
2015
Q3
$8.48M Sell
69,339
-5,613
-7% -$731K 0.14% 96
2015
Q2
$9.73M Buy
74,952
+700
+0.9% +$91.3K 0.14% 99
2015
Q1
$9.97M Sell
74,252
-290
-0.4% -$37.4K 0.15% 97
2014
Q4
$9.34M Sell
74,542
-4,438
-6% -$540K 0.14% 105
2014
Q3
$9.61M Sell
78,980
-14,625
-16% -$1.78M 0.15% 100
2014
Q2
$11M Buy
93,605
+2,670
+3% +$314K 0.17% 101
2014
Q1
$10.9M Sell
90,935
-825
-0.9% -$98.1K 0.18% 85
2013
Q4
$10.2M Sell
91,760
-670
-0.7% -$66.6K 0.16% 101
2013
Q3
$8.52M Sell
92,430
-3,045
-3% -$275K 0.15% 104
2013
Q2
$8.08M Buy
+95,475
New +$7.95M 0.15% 98

Other funds holding TMO

Levin Capital Strategies's TMO Position: Q1 2026 in Review

Levin Capital Strategies increased its Thermo Fisher Scientific (TMO) stake by 2.2% in Q1 2026, buying an estimated $74.9K and bringing the position to 6,291 shares worth $3.09M. The position accounts for 0.23% of the portfolio, ranked #87.

Levin Capital Strategies first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $103M in Q4 2016. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Levin Capital Strategies held 6,291 shares of Thermo Fisher Scientific worth $3.09M as of Q1 2026.
  • Levin Capital Strategies bought 138 Thermo Fisher Scientific shares in Q1 2026, an estimated $74.9K.
  • Thermo Fisher Scientific made up 0.23% of Levin Capital Strategies's portfolio in Q1 2026, its #87 holding.
  • Levin Capital Strategies first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Levin Capital Strategies's Thermo Fisher Scientific position peaked at $103M in Q4 2016.
  • 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Levin Capital Strategies's 13F filing for Q1 2026, filed 13 May 2026.